OABIW
OmniAb, Inc.
Price Chart
Latest Quote
$0.11
+0.00 (+0.00%)
Current Price
| Previous Close | $0.11 |
| Open | $0.17 |
| Day High | $0.11 |
| Day Low | $0.11 |
| Volume | 200 |
Stock Information
| Total Debt | $19.67M |
| Cash Equivalents | $49.07M |
| Revenue | $28.94M |
| Net Income | $-54.29M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Sales | $28.94M |
| Income | $-54.29M |
| Book/sh | $1.81 |
| Employees | 89 |
Financial Ratios
| Quick Ratio | 4.55 |
| Current Ratio | 4.80 |
| Debt/Eq | 7.49 |
Returns & Margins
| ROA | -11.32% |
| ROE | -20.25% |
| Gross Margin | 98.91% |
| Operating Margin | -54.27% |
| Profit Margin | -187.59% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.06 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.09 |
| SMA50 | $0.09 |
| RSI | nan |
| Shares Float | 113.87M |
| Volatility | 1.15 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| YTD | +0.33% |
| 10 Years | +0.33% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.09 | 0 |
| 2026-06-17 | $0.09 | 0 |
| 2026-06-16 | $0.09 | 0 |
| 2026-06-15 | $0.09 | 0 |
| 2026-06-12 | $0.09 | 0 |
| 2026-06-11 | $0.09 | 0 |
| 2026-06-10 | $0.09 | 0 |
| 2026-06-09 | $0.09 | 0 |
| 2026-06-08 | $0.09 | 0 |
| 2026-06-05 | $0.09 | 0 |
| 2026-06-04 | $0.09 | 0 |
| 2026-06-03 | $0.09 | 0 |
| 2026-06-02 | $0.09 | 0 |
| 2026-06-01 | $0.09 | 0 |
| 2026-05-29 | $0.09 | 0 |
| 2026-05-28 | $0.09 | 0 |
| 2026-05-27 | $0.09 | 0 |
| 2026-05-26 | $0.09 | 0 |
About OmniAb, Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
đ° Latest News
Companies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In Growth
Simply Wall St. âĸ 2026-06-02T10:20:26Z
OmniAb (OABI) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-08T14:10:29Z
OmniAb, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
OmniAb Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T11:07:39Z
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-08T02:25:07Z
Bullish OmniAb Insiders Loaded Up On US$1.28m Of Stock
Simply Wall St. âĸ 2026-04-22T11:55:17Z
OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026
Insider Monkey âĸ 2026-04-14T05:59:36Z
Here Is Why You Should Not Ignore OmniAb Inc. (OABI)
Insider Monkey âĸ 2026-03-31T07:19:06Z
John Higgins Bought 3.5% More Shares In OmniAb
Simply Wall St. âĸ 2025-11-13T10:51:47Z
Analysts Have Been Trimming Their OmniAb, Inc. (NASDAQ:OABI) Price Target After Its Latest Report
Simply Wall St. âĸ 2025-11-08T13:27:42Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $303,000 | $0 | - | - |
| Cost Of Revenue | $303,000 | $0 | - | - |
| Total Revenue | $18,666,000 | $26,391,000 | $34,164,000 | $59,077,000 |
| Operating Revenue | $18,666,000 | $26,391,000 | $34,164,000 | $59,077,000 |
| Expenses | ||||
| Total Expenses | $87,635,000 | $100,893,000 | $103,583,000 | $85,725,000 |
| Other Income Expense | $15,000 | $-15,000 | $1,000 | - |
| Other Non Operating Income Expenses | $15,000 | $-15,000 | $1,000 | - |
| Net Non Operating Interest Income Expense | $2,660,000 | $3,106,000 | $5,055,000 | $587,000 |
| Operating Expense | $87,332,000 | $100,893,000 | $103,583,000 | $85,725,000 |
| Other Operating Expenses | $-2,549,000 | $-2,365,000 | $191,000 | $-592,000 |
| General And Administrative Expense | $29,215,000 | $30,741,000 | $33,313,000 | $24,903,000 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-64,779,000 | $-62,033,000 | $-50,619,000 | $-22,334,000 |
| Net Interest Income | $2,660,000 | $3,106,000 | $5,055,000 | $587,000 |
| Interest Income | $2,660,000 | $3,106,000 | $5,055,000 | $587,000 |
| Normalized Income | $-64,779,000 | $-62,033,000 | $-50,619,000 | $-22,334,000 |
| Net Income From Continuing And Discontinued Operation | $-64,779,000 | $-62,033,000 | $-50,619,000 | $-22,334,000 |
| Total Operating Income As Reported | $-68,969,000 | $-74,502,000 | $-69,419,000 | $-26,648,000 |
| Net Income Common Stockholders | $-64,779,000 | $-62,033,000 | $-50,619,000 | $-22,334,000 |
| Net Income | $-64,779,000 | $-62,033,000 | $-50,619,000 | $-22,334,000 |
| Net Income Including Noncontrolling Interests | $-64,779,000 | $-62,033,000 | $-50,619,000 | $-22,334,000 |
| Net Income Continuous Operations | $-64,779,000 | $-62,033,000 | $-50,619,000 | $-22,334,000 |
| Pretax Income | $-66,294,000 | $-71,411,000 | $-64,363,000 | $-26,061,000 |
| Interest Income Non Operating | $2,660,000 | $3,106,000 | $5,055,000 | $587,000 |
| Operating Income | $-68,969,000 | $-74,502,000 | $-69,419,000 | $-26,648,000 |
| Depreciation Amortization Depletion Income Statement | $12,912,000 | $17,407,000 | $13,554,000 | $13,050,000 |
| Depreciation And Amortization In Income Statement | $12,912,000 | $17,407,000 | $13,554,000 | $13,050,000 |
| Amortization Of Intangibles Income Statement | $12,912,000 | $17,407,000 | $13,554,000 | $13,050,000 |
| Gross Profit | $18,363,000 | $26,391,000 | - | - |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-47,215,000 | $-50,919,000 | $-49,922,000 | $-8,399,000 |
| Reconciled Depreciation | $21,754,000 | $23,583,000 | $19,497,000 | $18,249,000 |
| EBITDA (Bullshit earnings) | $-47,215,000 | $-50,919,000 | $-49,922,000 | $-8,399,000 |
| EBIT | $-68,969,000 | $-74,502,000 | $-69,419,000 | $-26,648,000 |
| Diluted NI Availto Com Stockholders | $-64,779,000 | $-62,033,000 | $-50,619,000 | $-22,334,000 |
| Tax Provision | $-1,515,000 | $-9,378,000 | $-13,744,000 | $-3,727,000 |
| Amortization | $12,912,000 | $17,407,000 | $13,554,000 | $13,050,000 |
| Research And Development | $47,754,000 | $55,110,000 | $56,525,000 | $48,364,000 |
| Selling General And Administration | $29,215,000 | $30,741,000 | $33,313,000 | $24,903,000 |
| Other Gand A | $29,215,000 | $30,741,000 | $33,313,000 | $24,903,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $57,899,000 | $65,579,000 | $75,139,000 | $90,152,000 |
| Total Assets | $300,914,000 | $325,558,000 | $375,225,000 | $421,212,000 |
| Total Non Current Assets | $235,573,000 | $257,420,000 | $280,324,000 | $296,262,000 |
| Other Non Current Assets | $1,472,000 | $2,100,000 | $2,745,000 | $3,579,000 |
| Goodwill And Other Intangible Assets | $209,128,000 | $222,039,000 | $239,446,000 | $251,221,000 |
| Other Intangible Assets | $125,149,000 | $138,060,000 | $155,467,000 | $167,242,000 |
| Current Assets | $65,341,000 | $68,138,000 | $94,901,000 | $124,950,000 |
| Other Current Assets | $3,926,000 | $3,432,000 | $4,074,000 | $6,395,000 |
| Receivables | $7,390,000 | $5,272,000 | $3,844,000 | $30,290,000 |
| Accounts Receivable | $7,390,000 | $5,272,000 | $3,844,000 | $30,290,000 |
| Cash Cash Equivalents And Short Term Investments | $54,025,000 | $59,434,000 | $86,983,000 | $88,265,000 |
| Cash And Cash Equivalents | $25,524,000 | $27,598,000 | $16,358,000 | $33,390,000 |
| Cash Financial | - | - | - | $33,390,000 |
| Allowance For Doubtful Accounts Receivable | - | - | - | - |
| Gross Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $20,334,000 | $23,164,000 | $25,561,000 | $25,796,000 |
| Long Term Debt And Capital Lease Obligation | $16,455,000 | $19,382,000 | $22,075,000 | $24,016,000 |
| Current Debt And Capital Lease Obligation | $3,879,000 | $3,782,000 | $3,486,000 | $1,780,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $33,887,000 | $37,940,000 | $60,640,000 | $79,839,000 |
| Total Non Current Liabilities Net Minority Interest | $17,633,000 | $22,852,000 | $37,524,000 | $53,817,000 |
| Other Non Current Liabilities | $393,000 | $1,039,000 | $3,233,000 | $4,135,000 |
| Non Current Deferred Liabilities | $785,000 | $2,431,000 | $12,216,000 | $25,666,000 |
| Non Current Deferred Taxes Liabilities | $785,000 | $2,314,000 | $11,354,000 | $21,341,000 |
| Current Liabilities | $16,254,000 | $15,088,000 | $23,116,000 | $26,022,000 |
| Other Current Liabilities | $1,218,000 | $737,000 | $1,320,000 | $4,075,000 |
| Current Deferred Liabilities | $3,161,000 | $2,337,000 | $6,848,000 | $8,207,000 |
| Payables And Accrued Expenses | $2,208,000 | $2,764,000 | $6,215,000 | $7,859,000 |
| Payables | $1,879,000 | $2,297,000 | $5,645,000 | $6,456,000 |
| Accounts Payable | $1,879,000 | $2,297,000 | $4,411,000 | $2,971,000 |
| Other Payable | - | - | $1,234,000 | - |
| Total Tax Payable | - | - | $0 | $3,485,000 |
| Income Tax Payable | - | - | $0 | $3,485,000 |
| Equity | ||||
| Common Stock Equity | $267,027,000 | $287,618,000 | $314,585,000 | $341,373,000 |
| Total Equity Gross Minority Interest | $267,027,000 | $287,618,000 | $314,585,000 | $341,373,000 |
| Stockholders Equity | $267,027,000 | $287,618,000 | $314,585,000 | $341,373,000 |
| Gains Losses Not Affecting Retained Earnings | $12,000 | $27,000 | $50,000 | $9,000 |
| Other Equity Adjustments | $12,000 | $27,000 | $50,000 | $9,000 |
| Retained Earnings | $-166,179,000 | $-101,400,000 | $-39,367,000 | $11,252,000 |
| Other Equity Interest | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $144,308,383 | $121,599,488 | $116,859,468 | $115,218,229 |
| Share Issued | $144,308,383 | $121,599,488 | $116,859,468 | $115,218,229 |
| Tangible Book Value | $57,899,000 | $65,579,000 | $75,139,000 | $90,152,000 |
| Invested Capital | $267,027,000 | $287,618,000 | $314,585,000 | $341,373,000 |
| Working Capital | $49,087,000 | $53,050,000 | $71,785,000 | $98,928,000 |
| Capital Lease Obligations | $20,334,000 | $23,164,000 | $25,561,000 | $25,796,000 |
| Total Capitalization | $267,027,000 | $287,618,000 | $314,585,000 | $341,373,000 |
| Additional Paid In Capital | $433,180,000 | $388,979,000 | $353,890,000 | $330,100,000 |
| Capital Stock | $14,000 | $12,000 | $12,000 | $12,000 |
| Common Stock | $14,000 | $12,000 | $12,000 | $12,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $117,000 | $862,000 | $4,325,000 |
| Long Term Capital Lease Obligation | $16,455,000 | $19,382,000 | $22,075,000 | $24,016,000 |
| Current Deferred Revenue | $3,161,000 | $2,337,000 | $6,848,000 | $8,207,000 |
| Current Capital Lease Obligation | $3,879,000 | $3,782,000 | $3,486,000 | $1,780,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,788,000 | $5,468,000 | $5,247,000 | $4,101,000 |
| Current Accrued Expenses | $329,000 | $467,000 | $570,000 | $1,403,000 |
| Goodwill | $83,979,000 | $83,979,000 | $83,979,000 | $83,979,000 |
| Net PPE | $24,973,000 | $33,281,000 | $38,133,000 | $41,462,000 |
| Accumulated Depreciation | $-19,332,000 | $-12,901,000 | $-8,876,000 | $-5,188,000 |
| Gross PPE | $44,305,000 | $46,182,000 | $47,009,000 | $46,650,000 |
| Leases | $17,745,000 | $17,745,000 | $16,077,000 | $16,085,000 |
| Construction In Progress | $46,000 | $103,000 | $842,000 | $315,000 |
| Other Properties | $15,545,000 | $17,789,000 | $19,884,000 | $21,483,000 |
| Machinery Furniture Equipment | $10,969,000 | $10,545,000 | $10,206,000 | $8,767,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $28,501,000 | $31,836,000 | $70,625,000 | $54,875,000 |
| Dueto Related Parties Current | - | - | $1,234,000 | $0 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-37,020,000 | $-41,539,000 | $703,000 | $-20,755,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-36,455,000 | $-39,664,000 | $2,347,000 | $-3,587,000 |
| Cash Flow From Continuing Operating Activities | $-36,455,000 | $-39,664,000 | $2,347,000 | $-3,587,000 |
| Operating Gains Losses | $-3,000,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-565,000 | $-1,875,000 | $-1,644,000 | $-17,168,000 |
| Investing Cash Flow | $6,467,000 | $37,884,000 | $-18,376,000 | $-73,313,000 |
| Cash Flow From Continuing Investing Activities | $6,467,000 | $37,884,000 | $-18,376,000 | $-73,313,000 |
| Net Other Investing Changes | $3,000,000 | $-400,000 | $-4,440,000 | $-1,440,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $28,199,000 | $11,369,000 | $0 | $96,242,000 |
| Financing Cash Flow | $27,914,000 | $13,020,000 | $-892,000 | $110,739,000 |
| Cash Flow From Continuing Financing Activities | $27,914,000 | $13,020,000 | $-892,000 | $110,739,000 |
| Net Other Financing Charges | $-774,000 | $-1,606,000 | $-2,097,000 | $13,873,000 |
| Net Common Stock Issuance | $28,199,000 | $11,369,000 | $0 | $96,242,000 |
| Common Stock Issuance | $28,199,000 | $11,369,000 | $0 | $96,242,000 |
| Other | ||||
| End Cash Position | $26,084,000 | $28,158,000 | $16,918,000 | $33,839,000 |
| Beginning Cash Position | $28,158,000 | $16,918,000 | $33,839,000 | $0 |
| Changes In Cash | $-2,074,000 | $11,240,000 | $-16,921,000 | $33,839,000 |
| Proceeds From Stock Option Exercised | $489,000 | $3,257,000 | $1,205,000 | $624,000 |
| Net Investment Purchase And Sale | $4,032,000 | $40,159,000 | $-12,292,000 | $-54,705,000 |
| Sale Of Investment | $50,890,000 | $80,447,000 | $100,324,000 | $70,000 |
| Purchase Of Investment | $-46,858,000 | $-40,288,000 | $-112,616,000 | $-54,775,000 |
| Net PPE Purchase And Sale | $-565,000 | $-1,875,000 | $-1,644,000 | $-17,168,000 |
| Purchase Of PPE | $-565,000 | $-1,875,000 | $-1,644,000 | $-17,168,000 |
| Change In Working Capital | $-4,953,000 | $-10,172,000 | $24,871,000 | $-10,833,000 |
| Change In Other Working Capital | $-1,600,000 | $-5,988,000 | $-5,347,000 | $-9,489,000 |
| Change In Other Current Liabilities | $-2,830,000 | $-2,436,000 | $-563,000 | $1,827,000 |
| Change In Other Current Assets | $628,000 | $645,000 | $642,000 | $-788,000 |
| Change In Payables And Accrued Expense | $-231,000 | $-2,410,000 | $920,000 | $15,068,000 |
| Change In Payable | $-231,000 | $-2,410,000 | $920,000 | $15,068,000 |
| Change In Account Payable | $-231,000 | $-2,410,000 | $920,000 | $15,068,000 |
| Change In Prepaid Assets | $-1,109,000 | $642,000 | $2,321,000 | $-4,714,000 |
| Change In Receivables | $189,000 | $-625,000 | $26,898,000 | $-12,737,000 |
| Changes In Account Receivables | $189,000 | $-625,000 | $26,898,000 | $-12,737,000 |
| Other Non Cash Items | $1,086,000 | $-2,003,000 | $-241,000 | $-402,000 |
| Stock Based Compensation | $15,824,000 | $21,499,000 | $24,820,000 | $18,322,000 |
| Amortization Of Securities | $-858,000 | $-1,498,000 | $-3,441,000 | $-170,000 |
| Deferred Tax | $-1,529,000 | $-9,040,000 | $-12,540,000 | $-6,419,000 |
| Deferred Income Tax | $-1,529,000 | $-9,040,000 | $-12,540,000 | $-6,419,000 |
| Depreciation Amortization Depletion | $21,754,000 | $23,583,000 | $19,497,000 | $18,249,000 |
| Depreciation And Amortization | $21,754,000 | $23,583,000 | $19,497,000 | $18,249,000 |
| Gain Loss On Sale Of PPE | $-3,000,000 | $0 | - | - |
| Net Income From Continuing Operations | $-64,779,000 | $-62,033,000 | $-50,619,000 | $-22,334,000 |
| Income Tax Paid Supplemental Data | - | $16,000 | $2,614,000 | $0 |
| Net Business Purchase And Sale | - | - | - | - |
| Purchase Of Business | - | - | - | - |
| Net Intangibles Purchase And Sale | - | - | - | - |
| Sale Of Intangibles | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-18